

**North of Tyne, Gateshead and North Cumbria
Area Prescribing Committee**
www.northoftyneapc.nhs.uk
Tuesday 27th April 2021 12:30 pm
[Join Microsoft Teams Meeting](#)

AGENDA

1.	Apologies for absence Matt Grove Neil Watson	
2.	Declarations of interest	
3.	Appeals against previous decision None	
4.	Minutes from the meeting Decision summary from	Enc.1. Enc.2.
5.	Matters arising not on the agenda	
6.	APC Action log <ul style="list-style-type: none"> • Update 	Enc.3.
7.	Report from the Formulary sub-group <ul style="list-style-type: none"> • Draft minutes from meeting held on 25/2/21, including post meeting chairs approval of OxyPro. • Draft decision summary from meeting held on 25/2/21 	Enc.4. Enc.4b.
8.	Report from the Medicines Guidelines and Use Group <ul style="list-style-type: none"> • Draft minutes from meeting held on 1/3/21 • Guidance agreed to retire: <ul style="list-style-type: none"> ○ Recommendation to remove SPS NOAC table from APC website ○ Naltrexone guidance recommended to retire by MGUG in Sept 2020 • Guidance/documents to approve: <ul style="list-style-type: none"> ○ Preterm infant feeding guideline ○ Faltering growth guideline ○ Gender dysphoria guideline ○ Adult ADHD shared care guidance ○ Recommendation to: <ul style="list-style-type: none"> ▪ extend the expiry date on the current CMPA guidance by a year ▪ Extend review date on current kidney disease guideline to Dec 21 	Enc.5. Enc.6. Enc.7. Enc.8. Enc.9. Enc.10. Enc.11.
9.	Opiate/pain management sub-group <ul style="list-style-type: none"> • Update from meeting held on 17/3/21 • Data 	Enc.12. Enc.13.

10.	<p>RMOCs</p> <ul style="list-style-type: none"> Minor update to the Rarely Used and Urgent Medicines List Position Statement. https://www.sps.nhs.uk/articles/rarely-used-and-urgent-medicines-list/ “Shared Care for Medicines Guidance – A Standard Approach”. Buprenorphine guidance RMOc-Buprenorphine-guidance-Final-V1.0.pdf (sps.nhs.uk) 	<p>Email 23/2/21.</p> <p>Enc.14.</p>
11.	<p>RDTc Prescribing for population health Inhaler Carbon Footprint: Significance, Focus & Action</p>	<p>Enc.15.</p>
12.	<p>ICS update</p>	
13.	<p>Northern (NHS) Treatment Advisory Group (NTAG). http://ntag.nhs.uk/ The following recommendations were updated by NTAG at their meeting on the 23rd February 2021 and are now available on the website:</p> <ul style="list-style-type: none"> Flash Glucose Monitoring – updated. Teriparatide for atypical bisphosphonate induced fractures - reviewed and no changes made. Doxylamine/Pyridoxine (Xonvea®) for nausea & vomiting in pregnancy – reviewed and no changes made. <p>The following recommendations were archived by NTAG at their meeting on the 8th December 2020 as they are now superseded by NICE TA or NHSE guidance:</p> <ul style="list-style-type: none"> Erenumab and galcanezumab for prophylaxis of migraine Brolucizumab for wAMD 	<p>Enc.16. Enc.17.</p> <p>Enc.18.</p>
14.	<p>MHRA and NICE</p> <ul style="list-style-type: none"> MHRA Early Access to Medicines Scheme scientific opinion: Pemigatinib in the treatment of cholangiocarcinoma <p>NICE Technology Appraisals published since last meeting</p> <ul style="list-style-type: none"> TA670 Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor TA 671 Mepolizumab for treating severe eosinophilic asthma Update and replacement for NICE TA 431 TA672 Brolucizumab for treating wet age-related macular degeneration TA673 Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy TA674 Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) TA675 Vernakalant for the rapid conversion of recent 	

	<p>onset atrial fibrillation to sinus rhythm (terminated appraisal)</p> <ul style="list-style-type: none"> • TA676 Filgotinib for treating moderate to severe rheumatoid arthritis • TA677 Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma • TA679 Dapagliflozin for treating chronic heart failure with reduced ejection fraction <ul style="list-style-type: none"> ○ North Cumbria and Northumbria draft supplementary information – for discussion • TA680 Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma • TA681 Baricitinib for treating moderate to severe atopic dermatitis • TA682 Erenumab for preventing migraine • TA683 Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer • TA684 Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease • TA685 Anakinra for treating Still's disease • TA686 Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia : terminated appraisal • TA687 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy • TA689 Acalabrutinib for treating chronic lymphocytic leukaemia • TA690 Teduglutide for treating short bowel syndrome (terminated appraisal) • TA691 Avelumab for untreated metastatic Merkel cell carcinoma • HST14 Metreleptin for treating lipodystrophy - highly specialised technologies 	Enc.19 & 20
15.	<p>NHS England</p> <ul style="list-style-type: none"> • Specialised Services circulars <ul style="list-style-type: none"> ○ SSC2210 NICE Technology Appraisal Final Appraisal Determination: niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. ○ SSC2211 NICE Technology Appraisal Final Appraisal Determination: KTE-X19 (Tecartus®) for treating relapsed or refractory mantle cell lymphoma. ○ SSC2212 Early Access to Medicines Scheme – nivolumab in combination with ipilimumab for the first line treatment of adult patients with unresectable malignant pleural mesothelioma (MPM). ○ SSC2226 Early Access to Medicines Scheme – pemigatinib in the treatment of adults with locally 	Enc.21.

	<p>advanced or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that is relapsed or refractory after at least one line of systemic therapy</p> <ul style="list-style-type: none"> ○ SSC2228 Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy ○ SSC2229 Specialised services commissioning update ○ SSC2236: NICE Technology Appraisal - acalabrutinib for treating chronic lymphocytic leukaemia. ○ SSC2237 NICE Technology Appraisal Final Appraisal Determination - Pembrolizumab for previously treated advanced or metastatic urothelial cancer ○ SSC2238 NICE Technology Appraisal Final Appraisal Determination - olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer. ○ SSC2239 NICE Technology Appraisal Final Appraisal Determination - carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma. ○ SSC2240 NICE Technology Appraisal Final Appraisal Determination: avelumab for untreated metastatic Merkel cell carcinoma. ○ SSC2243 - Specialised Commissioning Update 	
16.	Chairman's action Approval of updated OAB guidance	Enc.22.
17.	Any other business	
18.	<p>Date, time and venue of next meetings Using Microsoft Teams on:</p> <ul style="list-style-type: none"> • Tuesday 13th July 12.30 pm • Tuesday 12th October 12.30 pm 	